Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

NCT05566795 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT05566795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05566795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 27, 2023
Completion date
June 30, 2031
Enrollment
418 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade glioma, pediatric low-grade glioma, rapidly accelerated fibrosarcoma (raf) altered glioma